Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MASCT by Hengrui Yuanzheng Biotechnology for Bone Sarcoma: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Bone Sarcoma. According to GlobalData,...
MASCT by Hengrui Yuanzheng Biotechnology for Soft Tissue Sarcoma: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Soft Tissue Sarcoma. According to...
MASCT by Hengrui Yuanzheng Biotechnology for Ureter Cancer: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Ureter Cancer. According to GlobalData,...
MASCT by Hengrui Yuanzheng Biotechnology for Metastatic Colorectal Cancer: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer. According to...
MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer)....
MASCT by Hengrui Yuanzheng Biotechnology for Solid Tumor: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData,...